Literature DB >> 1211410

Citrobacter diversus at Grace Hospital, Detroit, Michigan.

A Madrazo, J Geiger, C B Lauter.   

Abstract

Over a six-month period from December 1973 to June 1974, isolations of Citrobacter diversus were obtained from nine patients at Grace Hospital. Our initial experience was with a patient who developed pneumonitis and a massive fatal empyema due to this organism. Seven of the nine patients were 50 years of age. Three patients had an underlying malignancy. Four patients experienced significant clinical infections. Isolations in three patients were considered to be commensal, and two isolations were of indeterminate significance. Our Citrobacter diversus isolates, which can be confused with Escherichia coli, were uniformly resistant to ampicillin and carbenicillin and sensitive to the cephalosporins, tetracyclines, and gentamicin. These results agree with previous reports. Citrobacter diversus appears to be capable of causing serious clinical disease. Patients most at risk are elderly compromised hosts and infections are usually hospital acquired.

Entities:  

Mesh:

Year:  1975        PMID: 1211410     DOI: 10.1097/00000441-197511000-00011

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  4 in total

1.  Antigenic scheme of Citrobacter koseri.

Authors:  I Sechter; G Altmann; D Cahan; I Braunstein; C B Gerichter
Journal:  J Clin Microbiol       Date:  1981-12       Impact factor: 5.948

Review 2.  Bifocal cervical spondylodiscitis due to Citrobacter diversus.

Authors:  A Sotto; J C Bernard; C Brunschwig; D Blin; F M Lopez; B Combe
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

3.  Review of Citrobacter bacteremia in cancer patients over a sixteen-year period.

Authors:  G Samonis; E Anaissie; L Elting; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-06       Impact factor: 3.267

4.  Antimicrobial susceptibility patterns of urinary pathogens in Trinidad, 1996-1999.

Authors:  F A Orrett
Journal:  J Natl Med Assoc       Date:  2003-05       Impact factor: 1.798

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.